Market Place
Sourcing Support
Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023
28 Aug 2023 //
BUSINESSWIRE
HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301
23 Jun 2023 //
BUSINESSWIRE
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
06 Jan 2023 //
BUSINESSWIRE
HiFiBiO and Novartis to assess HFB200603 and tislelizumab combination
21 Nov 2022 //
CLINICALTRIALSARENA
HiFiBiO Announces Clinical Trial Supply Agreement to Evaluate HFB200603
18 Nov 2022 //
BUSINESSWIRE
HiFiBiO Announces Clinical Trial Supply Agreement to Evaluate HFB200301
15 Aug 2022 //
BUSINESSWIRE
HiFi Reads Enable Telomere-to-Telomere to Fill the Final Gaps in Human Genome
31 Mar 2022 //
GLOBENEWSWIRE
FibroGen & HiFiBiO Announce Partnership in Cancer and Autoimmune Disease
17 Jun 2021 //
GLOBENEWSWIRE
HiFiBiO Therapeutics Closes $75 Million Series D Financing
14 Jun 2021 //
BUSINESSWIRE
HiFiBiO Therapeutics Closes $75 Million Series D Financing
14 Jun 2021 //
BUSINESSWIRE
HiFiBiO snags investor high-fives with $75M for clinic launch
14 Jun 2021 //
FIERCEBIOTECH
HiFiBiO Announces Publication in Nature Communications on its SARS-CoV-2
11 May 2021 //
BUSINESSWIRE
HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2
26 Oct 2020 //
BUSINESSWIRE
HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio
14 Sep 2020 //
BUSINESSWIRE
Kite partners with HiFiBiO to develop cell therapies in AML
04 Sep 2020 //
PMLIVE
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement
28 Aug 2020 //
GLOBENEWSWIRE
HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2
25 Aug 2020 //
BUSINESSWIRE
HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium
17 Aug 2020 //
BUSINESSWIRE
HiFiBiO Presents Three Novel Immuno-Oncology Programs at 2020 AACR
22 Jun 2020 //
BUSINESSWIRE
HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise
15 May 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.